HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Dietary Supplement Market US FDA Is Regulating Isn’t Your 1994 DSHEA Version

Executive Summary

“In the last 30 years, we've seen this sort of explosion, and it's not just more products and more sales. We're talking about more complex products,” says Cara Welch, FDA Office of Dietary Supplement Programs director. “Today's products are not the products from 1994.”

You may also be interested in...



Absent Mandatory Listing, US FDA Acknowledges Its Supplement Directory Isn’t Comprehensive

Two weeks after Commissioner Califf notes he supports mandatory listing of supplements and two months after previous session of Congress ended without imposing requirement, agency is doing what it can to publish information about ingredients in supplements sold in the country.

US Consumer Health Industry In 2023: Mandatory Listing Has Supplement Sector’s Attention

Chief executives of OTC drug and supplement industry trade groups discussed potential market and regulatory developments affecting their members’ businesses. HBW Insight reports here on whether support will emerge in Congress for FDA to gain MPL authority for all supplements sold in US.

US FDA Allows Supplement Firms More Time To Submit NDI Notifications, And For It To Respond

More time for notifications than current deadline of at least 75 days before NDI-containing product is offered for sale in US doesn’t solve problems with FDA’s management of NDI regulation, say trade groups.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153680

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel